Summary

Gastrointestinal disease is a very common and frequently occurring disease, with a wide range of types and a total incidence of about 20% of the population. The cause of gastrointestinal disease is the imbalance between the protective mechanism and the injury mechanism of the human body. While traditional medicine kills harmful bacteria in the stomach, it also kills the beneficial bacteria necessary for the stomach. Although the symptoms are alleviated and inflammation is eliminated, the reduction of beneficial bacteria reduces the gastrointestinal immunity. Once the drug is stopped, it is easy to re-infect. There are many reasons for stomach problems, including genetics, environment, diet, drugs, bacterial infections, etc., as well as smoking and excessive alcohol consumption. This collection of entries aims to collect various items related to the topic of gastrointestinal diseases, such as clinical care, case cases, disease research, etc., to help people increase their knowledge and understanding of this common disease

Expand All
Entries
Topic Review
Therapeutic Approaches for Gastric Neuroendocrine Neoplasms
Gastric neuroendocrine neoplasms (gNENs) represent rare but increasingly recognized tumors. They are distinguished into three main clinical types (type-1, type-2, and type-3) according to gastrin level and at histological evaluation in well-differentiated G1, G2, or G3 lesions, as well as poorly-differentiated lesions.
  • 304
  • 13 Oct 2023
Topic Review
Therapeutic Applications of Bacteriophages in the Gut Microbiota
Bacteriophages (phages) are nano-sized viruses characterized by their inherent ability to live off bacteria. They utilize diverse mechanisms to absorb and gain entry into the bacterial cell wall via the release of viral genetic material, which uses the replication mechanisms of the host bacteria to produce and release daughter progeny virions that attack the surrounding host cells. They possess specific characteristics, including specificity for particular or closely related bacterial species. They have many applications, including as potential alternatives to antibiotics against multi-resistant bacterial pathogens and as control agents in bacteria-contaminated environments. They are ubiquitously abundant in nature and have diverse biota, including in the gut. Gut microbiota describes the community and interactions of microorganisms within the intestine. As with bacteria, parasitic bacteriophages constantly interact with the host bacterial cells within the gut system and have obvious implications for human health.
  • 325
  • 17 Oct 2023
Topic Review
Bioactive Compounds of Dietary Origin on Colorectal Cancer
Colorectal cancer (CRC) is one of the most common causes of death and the third most diagnosed cancer worldwide, one of the main risk for developing CRC is a diet high in fat and carbohydrates which stimulates an inflammatory state increasing reactive oxygen species (ROS). Dietary Bioactive compounds have antioxidant proprieties and participates in gut microbiota modulation, decreasing reactive oxygen species and inflammation, both principal causes of cancer. These compounds can promote apoptosis and inhibit cell growth, proliferation, and migration of colorectal cancer cells modulating molecular pathways related to CRC. The multidisciplinary tratment of CRC requires a Nutritional intervention since patient nutritional status affects treatment response and the progression or recurrence of the tumor
  • 367
  • 12 Oct 2023
Topic Review
The Melanocortin System in Inflammatory Bowel Diseases
The melanocortin system is a complex set of molecular mediators and receptors involved in many physiological and homeostatic processes. These include the regulation of melanogenesis, steroidogenesis, neuromodulation and the modulation of inflammatory processes. In the latter context, the system has assumed importance in conditions of chronic digestive inflammation, such as inflammatory bowel diseases (IBD), in which numerous experiences have been accumulated in mouse models of colitis.
  • 399
  • 28 Sep 2023
Topic Review
Screening for NAFLD in the Outpatient Pharmacy
Non-alcoholic fatty liver disease (NAFLD) stands as an increasingly pressing global health challenge, underscoring the need for timely identification to facilitate effective treatment and prevent the progression of chronic liver disorders. Given the projected scarcity of specialized healthcare professionals, particularly hepatologists and gastroenterologists, the role of pharmacists emerges as pivotal in NAFLD management. 
  • 265
  • 28 Sep 2023
Topic Review
PD-L1 Expression as a Biomarker in Gastric Cancer
Despite advances in diagnostic imaging, surgical techniques, and systemic therapy, gastric cancer (GC) is the third leading cause of cancer-related death worldwide. Unfortunately, molecular heterogeneity and, consequently, acquired resistance in GC are the major causes of failure in the development of biomarker-guided targeted therapies. However, by showing promising survival benefits in some studies, the recent emergence of immunotherapy in GC has had a significant impact on treatment-selectable procedures. Immune checkpoint inhibitors (ICIs), widely indicated in the treatment of several malignancies, target inhibitory receptors on T lymphocytes, including the programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) axis and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and release effector T-cells from negative feedback signals. 
  • 300
  • 26 Sep 2023
Topic Review
Reevaluating Therapeutic Use of Antibiotics in Liver Cirrhosis
Impairments in liver function lead to different complications. As chronic liver disease progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to changes in gut microbiota and, therefore, in the host–microbiome interaction, leading to a proinflammatory state. Alterations in gut microbiota composition and permeability, known as gut dysbiosis, have important implications in CLD; alterations in the gut–liver axis are a consequence of liver disease, but also a cause of CLD. Furthermore, gut dysbiosis plays an important role in the progression of liver cirrhosis and decompensation, particularly with complications such as hepatic encephalopathy and spontaneous bacterial peritonitis.
  • 268
  • 26 Sep 2023
Topic Review
The Role of Intestinal Microbiome in Constipation
The gut microbiota represents a community of microorganisms (bacteria, fungi, archaea, viruses, and protozoa) that colonize the gut and are responsible for gut mucosal structural integrity and immune and metabolic homeostasis. The relationship between the gut microbiome and human health has been intensively researched in the past years. The gut microbial population plays a key role in intestinal motility, and dysbiosis has been correlated with chronic constipation.
  • 266
  • 22 Sep 2023
Topic Review
Krüppel-like Factors 4 and 5 in Colorectal Tumorigenesis
Krüppel-like factors (KLFs) are transcription factors regulating various biological processes such as proliferation, differentiation, migration, invasion, and homeostasis. Importantly, they participate in disease development and progression. KLFs are expressed in multiple tissues, and their role is tissue- and context-dependent. KLF4 and KLF5 are two fascinating members of this family that regulate crucial stages of cellular identity from embryogenesis through differentiation and, finally, during tumorigenesis. They maintain homeostasis of various tissues and regulate inflammation, response to injury, regeneration, and development and progression of multiple cancers such as colorectal, breast, ovarian, pancreatic, lung, and prostate, to name a few.
  • 213
  • 12 Sep 2023
Topic Review
Sweeteners and Gut Microbiome
Worldwide, the demand for natural and synthetic sweeteners in the food industry as an alternative to refined sugar is increasing. This has prompted more research to be conducted to estimate its safety and effects on health. The gut microbiome is critical in metabolizing selected sweeteners which might affect overall health. Recently, more studies have evaluated the relationship between sweeteners and the gut microbiome.
  • 343
  • 19 Oct 2023
  • Page
  • of
  • 39

Featured Entry Collections

>>